Patents Assigned to PharmaEssentia Corporation
  • METHOD FOR PREVENTING OR TREATING LIVER DISEASE
    Publication number: 20240139142
    Abstract: Provided is a method for preventing or treating a liver disease, including administering a therapeutically effective amount of pharmaceutical composition to a subject in need, and the pharmaceutical composition includes the isothiocyanate structural modified compound and a pharmaceutically acceptable carrier thereof.
    Type: Application
    Filed: September 14, 2023
    Publication date: May 2, 2024
    Applicants: TAIPEI VETERANS GENERAL HOSPITAL, NATIONAL YANG MING CHIAO TUNG UNIVERSITY, PHARMAESSENTIA CORPORATION
    Inventors: Jaw-Ching WU, Yung-Sheng CHANG, Kuo-Hsi KAO, Chan-Kou HWANG, Ko-Chung LIN
  • Dosage regimen for pegylated interferon
    Patent number: 11559567
    Abstract: A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 ?g dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 24, 2023
    Assignee: PharmaEssentia Corporation
    Inventors: Christoph Klade, Oleh Zagrijtschuk, Ko-Chung Lin
  • NOVEL SYNTHESIS OF BETA-NUCLEOSIDES
    Publication number: 20090124797
    Abstract: This invention relates to a process of stereoselectively synthesizing ?-nucleoside, e.g., 2?-deoxy-2,2?-difluorocytidine.
    Type: Application
    Filed: November 6, 2008
    Publication date: May 14, 2009
    Applicant: PharmaEssentia Corporation
    Inventors: Chi-Yuan Chu, Wei-Der Lee, Wensen Li, Chan Kou Hwang